After a strong first half for biotech in 2026, the market pause in the third quarter is likely to extend through year-end ...

Treatments for rare diseases accounted for six of the nine NMEs CDER approved in September, including the first approved therapies for MCT8 deficiency and ...

Cardiovascular drug developers are trying to undo in a few years the effects of pathways that have shaped disease over a lifetime. A series of late-stage ...

A small group of specialist biotechs is advancing antifungals that could expand treatment options for invasive fungal ...

Brain shuttle technology is entering a new phase. A year after BioCentury mapped a field led by protein therapeutics, much of ...

RougeTx believes restoring blood vessel stability could offer a better way to treat hereditary hemorrhagic telangiectasia ...

“GluFormer” could improve metabolic risk stratification by extracting predictive representations from longitudinal continuous glucose monitoring data. The generative foundation model was trained by se ...

Earlier-stage and more modality-diverse China-origin assets are attracting multibillion-dollar licensing deals, ...

The Trump administration’s GLOBE model has shriveled, and in the process, the threat it poses to biomedical innovation has ...

Three deals in the last week underscore a shift in pharma’s China partnering toward a wider range of therapies — and ...

At Jefferies in New York this June, Albert Bourla, CEO and chairman of Pfizer, piqued my interest. He said: “The way I see it ...

Revier is targeting class IIa histone deacetylases (HDACs), whose enzymatic activity is mostly dormant in healthy cells but ...